Rationale Lack of an experimental model of portopulmonary hypertension (POPH) has been a major obstacle in understanding of pathophysiological mechanisms underlying the disease. Objective We investigated the effects of CCl4-mediated cirrhosis on the pulmonary vasculature, as an initial step towards an improved understanding of POPH. Methods And Results Male C57BL/6 mice received intraperitoneal injection of either sterile olive oil or CCl4 3 times/week for 12 weeks. Cirrhosis and portal hypertension were confirmed by evidence of bridging fibrosis and nodule formation in CCl4-treated liver determined by trichrome/picrosirius red staining and an increase in spleen weight/body weight ratio, respectively. Staining for the oxidative stress marker, 4-hydroxynonenal (4-HNE), was strong in the liver but was absent in the lung, suggesting that CCl4 did not directly induce oxidative injury in the lung. Pulmonary acceleration time (PAT) and the ratio of PAT/pulmonary ejection time (PET) measured by echocardiography were significantly decreased in cirrhotic mice. Increase in right ventricle (RV) weight/body weight as well as in the weight ratio of RV/(left ventricle + septum) further demonstrated the presence of pathological changes in the pulmonary circulation in these mice. Histological examination revealed that lungs of cirrhotic mice have excessive accumulation of perivascular collagen and thickening of the media of the pulmonary artery. Conclusion Collectively, our data demonstrate that chronic CCl4 treatment induces pathological changes in pulmonary circulation in cirrhotic mice. We propose that this murine cirrhotic model provides an exceptional tool for future studies of the molecular mechanisms mediating pulmonary vascular diseases associated with cirrhosis and for evaluation of novel therapeutic interventions.
References
[1]
Machicao VI, Balakrishnan M, Fallon MB (2014) Pulmonary complications in chronic liver disease. Hepatology. 59: 1627–1637.
[2]
Ma C, Crippin JS, Chapman WC, Korenblat K, Vachharajani N, et al. (2013) Parenchymal alterations in cirrhotic livers in patients with hepatopulmonary syndrome or portopulmonary hypertension. Liver Transpl. 19: 741–750.
[3]
Krowka MJ, Miller DP, Barst RJ, Taichman D, Dweik RA, et al. (2012) Portopulmonary hypertension: a report from the US-based REVEAL Registry. Chest. 141: 906–915.
[4]
Aguirre-Avalos G, Covarrubias-Velasco MA, Rojas-Sánchez AG (2013) Venous outflow obstruction and portopulmonary hypertension after orthotopic liver transplantation. Am J Case Rep. 4: 354–358.
Fix OK, Bass NM, De Marco T, Merriman RB (2007) Long-term follow-up of portopulmonary hypertension: effect of treatment with epoprostenol. Liver Transpl. 13: 875–885.
[7]
Tsiakalos A, Hatzis G, Moyssakis I, Karatzaferis A, Ziakas PD, et al. (2011) Portopulmonary hypertension and serum endothelin levels in hospitalized patients with cirrhosis. Hepatobiliary Pancreat Dis Int. 10: 393–398.
[8]
Moon SB, Jung SE, Ha JW, Park KW, Seo JK, et al. (2008) The usefulness of distal splenorenal shunt in children with portal hypertension for the treatment of severe thrombocytopenia and leukopenia. World J Surg. 32: 483–487.
[9]
Marques TG, Chaib E, da Fonseca JH, Louren？o AC, Silva FD, et al. (2012) Review of experimental models for inducing hepatic cirrhosis by bile duct ligation and carbon tetrachloride injection. Acta Cir Bras. 27: 589–594.
[10]
Kim SG, Chung HC, Cho JY (1996) Molecular mechanism for alkyl sulfide-modulated carbon tetrachloride-induced hepatotoxicity: the role of cytochrome P450 2E1, P450 2B and glutathione S-transferase expression. J Pharmacol Exp Ther. 277: 1058–1066.
[11]
Boerma M, Wang J, Sridharan V, Herbert JM, Hauer-Jensen M (2013) Pharmacological induction of transforming growth factor-beta1 in rat models enhances radiation injury in the intestine and the heart. PLoS One. 8: e70479.
[12]
Berzigotti A, Seijo S, Arena U, Abraldes JG, Vizzutti F, et al. (2013) Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. Gastroenterology. 144: 102–111.
[13]
Kolosionek E, King J, Rollinson D, Schermuly RT, Grimminger F, et al. (2013) Schistosomiasis causes remodeling of pulmonary vessels in the lung in a heterogeneous localized manner: Detailed study. Pulm Circ. 3: 356–362.
[14]
Geerts AM, Vanheule E, Praet M, Van Vlierberghe H, De Vos M, et al. (2008) Comparison of three research models of portal hypertension in mice: macroscopic, histological and portal pressure evaluation. Int J Exp Pathol. 89: 251–263.
[15]
Hartley DP, Kolaja KL, Reichard J, Petersen DR (1999) 4-Hydroxynonenal and malondialdehyde hepatic protein adducts in rats treated with carbon tetrachloride: immunochemical detection and lobular localization. Toxicol Appl Pharmacol. 161: 23–33.
[16]
Yared K, Noseworthy P, Weyman AE, McCabe E, Picard MH, et al. (2011) Pulmonary artery acceleration time provides an accurate estimate of systolic pulmonary arterial pressure during transthoracic echocardiography. J Am Soc Echocardiogr. 24: 687–692.
[17]
Das M, Fessel J, Tang H, West J (2012) A process-based review of mouse models of pulmonary hypertension. Pulm Circ. 2: 415–433.
[18]
Henkel M, Paquet KJ, Rühl U (1994) Correlation between pulmonary hypertension and portal hypertension—2 case reports of different forms of pre-sinusoidal portal hypertension. Leber Magen Darm. 24: 10–14.
[19]
Mizuguchi S, Takemura S, Minamiyama Y, Kodai S, Tsukioka T, et al. (2006) S-allyl cysteine attenuated ccl4-induced oxidative stress and pulmonary fibrosis in rats. BioFactors 26: 81–92.
[20]
Salatti Ferrari R, da Rosa DP, Forgiarini LF, Bona S, Dias AS, et al. (2012) Oxidative stress and pulmonary changes in experimental liver cirrhosis. Oxid Med Cell Longev. 2012: 486190.
Sulica R, Emre S, Poon M (2004) Medical management of porto-pulmonary hypertension and right heart failure prior to living-related liver transplantation. Congest Heart Fail. 10: 192–194.
Ganie SA, Haq E, Hamid A, Qurishi Y, Mahmood Z, et al. (2011) Carbon tetrachloride induced kidney and lung tissue damages and antioxidant activities of the aqueous rhizome extract of Podophyllum hexandrum. BMC Complement Altern Med. 11: 17.
[25]
Urboniene D, Haber I, Fang YH, Thenappan T, Archer SL (2010) Validation of high-resolution echocardiography and magnetic resonance imaging vs. high-fidelity catheterization in experimental pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 299: L401–L412.
[26]
Rydell-T？rm？nen K, Risse PA, Kanabar V, Bagchi R, Czubryt MP, et al. (2013) Smooth muscle in tissue remodeling and hyper-reactivity: airways and arteries. Pulm Pharmacol Ther. 26: 13–23.
